Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 2/20 | 0.37 |
| ▸ | CASP3 | P42574 | 2/20 | 0.37 |
| ▸ | CASP7 | P55210 | 2/20 | 0.37 |
| ▸ | CASP6 | P55212 | 2/20 | 0.37 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.37 |
| ▸ | CTSS | P25774 | 4/20 | 0.36 |
| ▸ | CTSK | P43235 | 3/20 | 0.36 |
| ▸ | CTSL | P07711 | 3/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15218764 | 0.88 | REN (0.34) | REN | |
| SCHEMBL14788400 | 0.86 | REN (0.47) | REN | |
| SCHEMBL7343601 | 0.86 | REN (0.47) | REN | |
| SCHEMBL9928632 | 0.86 | REN (0.47) | REN | |
| SCHEMBL4640296 | 0.83 | REN (0.42) | REN | |
| SCHEMBL14791593 | 0.82 | REN (0.48) | REN | |
| SCHEMBL16511409 | 0.82 | REN (0.48) | REN | |
| SCHEMBL429920 | 0.81 | REN (0.39) | REN | |
| SCHEMBL429921 | 0.81 | REN (0.39) | REN | |
| SCHEMBL429922 | 0.81 | REN (0.39) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664440-B2 | Method for preparing aliskiren and its intermediates thereof | ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD (CN) | 2014-03-04 | — | — | US | disclosed |
| US-20130225841-A1 | METHOD FOR PREPARING ALISKIREN AND ITS INTERMEDIATES THEREOF | ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD. (CN) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225841-A1 | METHOD FOR PREPARING ALISKIREN AND ITS INTERMEDIATES THEREOF | FLI1, MLX, LMTK2 | REN 166/4885CASP1 2717/4885CASP3 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.